Reliability and Validity Studies of Turkish Version of Manual Ability Measure-36

Reliability and Validity Studies of Turkish Version of Manual Ability Measure-36 (MAM-36)

This study aim was to investigate the validity and reliability of Turkish version of Manual Ability Measure-36 (MAM-36) in patients with neurological disease.

Study Overview

• Status: Completed
• Conditions: Stroke; Multiple Sclerosis; Parkinson Disease; Upper Extremity Problem
• Intervention / Treatment: Other: Turkish Validity and Reliability of The MAM-36 Scale

Detailed Description

The reliability and validity of the scale were initiated by language equivalence and cultural adaptation. The MAM-36 scale was translated into Turkish by two experienced physiotherapists who are native Turkish speakers and have a good command of English, following the translation procedures. The two translations were compared with each other and a single Turkish draft was created. This draft was translated back into English by two translators who are native English speakers and have a good command of Turkish. The two back translations were compared to each other and converted into a single form. The resulting form was compared with the original form and the final back-translation scale was created. All translation formats of the scale were examined in detail by those who translated the scale into Turkish and a jury consisting of experienced physiotherapists. At the end of the meeting, the pilot study form of the scale was created. The created draft was applied to 30 healthy individuals as a pilot study. The final version of the scale was created by evaluating the feedback obtained. The clinical phase of the study was carried out on 250 volunteer individuals who applied to Dokuz Eylül University Hospital Neurology Department Polyclinics and were diagnosed with MS, Parkinson's disease, and stroke, and who had various degrees of problems in hand dexterity and functions due to their diseases. To evaluate the validity of MAM-36, Disability of Arm Shoulder and Hand (DASH), which can measure manual dexterity and was validated in Turkish, was used. The scales were repeated 15 days later to assess test-retest reliability.

• Study Type: Observational
• Enrollment (Actual): 250

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Individuals who were diagnosed with stroke, Parkinson's or Multiple Sclerosis and had problems with manual dexterity in at least one upper extremity were included in the study.

Description

Inclusion Criteria:

• Being diagnosed with a neurological disease (Stroke, Parkinson's or MS)
• At least one upper extremity is affected
• Being conscious enough to complete the survey and knowing how to read and write
• Agreeing to participate in the research
• Being over 18 years old

Exclusion Criteria:

• Having an upper extremity operation within the last 6 months
• Having had an attack or seizure in the last month
• Participating in any physical therapy program during the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Manual Ability Measure-36	Manual Ability Measure-36 was used to measure hand functions. The scale is a task- and patient-oriented measurement tool. Scale items consist of tasks that are frequently performed in daily life. In the survey where individuals subjectively evaluate their manual skills, a 4-point Likert rating scale is used, where 1 is 'I cannot do', 2 is 'very difficult', 3 is 'somewhat difficult', 4 is 'easy'. As a result of this 4-grade scoring of the scale, each patient receives a score between 0-144 from the test. However, in order to facilitate the analysis of future studies on the scale, a 100-point conversion table was created by the creators of the test.	baseline
Disability of Arm Shoulder and Hand	Disability of Arm Shoulder and Hand (DASH) was developed by the 'Institute of Work and Health Ontario and American Academy of Orthopedic Surgeons' for use in patients with upper extremity problems. DASH is a self-report scale that measures activity and participation limitations and level of disability in upper extremity disorders. The patient's symptoms and daily life activities are examined on a scale consisting of thirty questions. Grading of the scale is done with a Likert scale. For each task, the patient gives a difficulty rating between 1 and 5. These five difficulty levels are defined as 1: no difficulty, 2: mild difficulty, 3: moderate difficulty, 4: extreme difficulty, 5: not at all. A score between 0-100 (0 = no apology, 100 = maximum apology) is obtained from the scale. A high score also indicates high functional disability. The scale has a Turkish cultural adaptation.	baseline

Collaborators and Investigators

• Sponsor: Istanbul Medeniyet University

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2016
• Primary Completion (Actual): January 25, 2017
• Study Completion (Actual): June 30, 2017

Study Registration Dates

• First Submitted: November 3, 2023
• First Submitted That Met QC Criteria: November 3, 2023
• First Posted (Actual): November 8, 2023

Study Record Updates

• Last Update Posted (Estimated): February 6, 2024
• Last Update Submitted That Met QC Criteria: February 3, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Multiple Sclerosis; Parkinson Disease
• Other Study ID Numbers: 2663-GOA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No